Skip Navigation


JAC Advance Access originally published online on June 10, 2008
Journal of Antimicrobial Chemotherapy 2008 62(3):639-640; doi:10.1093/jac/dkn227
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/3/639    most recent
dkn227v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Luna, V. A.
Right arrow Articles by Cattani, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luna, V. A.
Right arrow Articles by Cattani, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Susceptibility of 170 isolates of the USA300 clone of MRSA to macrolides, clindamycin and the novel ketolide cethromycin

Vicki Ann Luna1,*, Ze-Qi Xu2, David A. Eiznhamer2, Andrew C. Cannons1 and Jacqueline Cattani1

1 Center for Biological Defence, College of Public Health, University of South Florida, 3602 Spectrum Boulevard, Tampa, FL 33612, USA 2 Advanced Life Sciences, 1440 Davey Road, Woodridge, IL 60517, USA

* Corresponding author. Tel: +1-813-974-3873; Fax: +1-813-974-1479; E-mail: vluna@health.usf.edu

Keywords: MIC , ketolide , antimicrobial activity

The first 10% of the full text of this article appears below.

Sir,

Historically, methicillin-resistant Staphylococcus aureus (MRSA) has been regarded as a nosocomial pathogen responsible for severe toxin-mediated disease or invasive pyogenic infections. In recent years, however, community-associated MRSA (CA-MRSA) has been reported from around the world. Although the first CA-MRSA strains were susceptible to most antimicrobials, antimicrobial resistance has increased. One CA-MRSA clone, identified by the CDC as pulsotype USA300, has been implicated in outbreaks within the USA and is resistant to many currently marketed antimicrobial agents.1 This clone carries both the SCCmec IV element and the Panton–Valentine leukocidin (PVL) locus. The aim of this study was to compare the activity of a novel ketolide, cethromycin (previously ABT-773), with potentially improved . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?